Second big M&A deal of 2019: Lilly to acquire Loxo

Eli Lilly and Co. (NYSE:LLY) said on Jan. 7 it reached an $8 billion agreement to acquire Loxo Oncology Inc. (NASDAQ:LOXO), the pharma's third cancer-focused acquisition in the past year. The deal also comes in the wake of the proposal the week prior by Bristol-Myers Squibb Co. (NYSE:BMY) to acquire Celgene Corp. (NASDAQ:CELG) for about $74 billion (see "Bristol-Myers' Next Phoenix Act?").

Loxo shareholders will receive $235 per

Read the full 676 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE